Resistance to -lactam antibiotics has been a problem for as long as these drugs have been used in clinical practice. In clinically significant bacteria the most important mechanism of resistance is the production of one or more -lactamases, enzymes that hydrolyse the -lactam bond characteristic of this family of antibiotics. Prominent among the -lactamases produced by the Enterobacteriaceae is the SHV family. The first reported SHV -lactamase had a narrow spectrum of activity. By the accumulation of point mutations at sites that affect the active site of the enzyme, a family of derivatives of SHV-1 has evolved. Derivatives of SHV-1 either have an extended spectrum of activity, capable of inactivating third-generation cephalosporins, or are resistant to -lactamase inhibitors. This review describes the evolution and spread of the SHV family of -lactamases, introducing the structure-function analysis made possible by DNA sequence analysis. It also reviews the methods used to characterize members of this family of -lactamases, indicating some of the difficulties involved. sequence homology studies were able to resolve difficulties with previous classification schemes.
Introduction
Since their introduction into clinical practice, the effectiveness of -lactam antibiotics has been reduced by the occurrence of bacteria that are resistant to their mode of action. Resistant Staphylococcus aureus were reported very soon after the introduction of benzylpenicillin into clinical practice. Other than the intrinsic resistance resulting from insusceptible targets or inadequate penetration of the drug through the Gram-negative outer membrane, resistance to this class of antibiotic is most frequently due to the production of enzymes that hydrolyse the -lactam bond in these antibiotics, thus destroying their functionality. These enzymes are the -lactamases. 1 The introduction of the semi-synthetic penicillins and the early cephalosporins in the 1960s broadened the spectrum of activity of -lactams. These newer drugs could be used to treat Gram-negative infections, including lifethreatening conditions. As with the staphylococci, however, the problem of -lactam resistance rapidly emerged in Gram-negative bacteria. In clinically significant bacteria, resistance to -lactams was due to the production of -lactamases and amongst the most important of these were the TEM and SHV enzymes.
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Classification of -lactamases
The classification and nomenclature of -lactamases has always proved problematic. Several schemes have been proposed for the classification of this large family of enzymes. The first proposal was to divide -lactamases into the penicillinases that hydrolysed penicillins and cephalosporinases that attacked cephalosporins. The biochemical activity and substrate profiles of different enzymes formed the basis of other early classification schemes. [4] [5] [6] Later, the location of the genetic determinants, whether plasmid mediated or chromosomal, became incorporated into classification schemes. Data from isoelectric focusing studies and enzyme kinetics were also considered important and these, too, formed the basis of subsequent classifications. 7, 8 These schemes all had major anomalies but, following rapid developments in molecular biology, [9] [10] [11] [12] [13] [14] [15] As with classification schemes, there has also been considerable confusion over the nomenclature of -l a c t a m a s e s . There is no rational basis for the naming of these enzymes. The name 'TEM' is a contraction of Temoniera, the name of a patient from whom resistant bacteria were isolated. In contrast, 'SHV' is a contraction of sulphydryl variable: a description of the biochemical properties of thislactamase. Furthermore, -lactamases may be given one name when first identified, only to have this name changed after subsequent studies have allowed a more complete characterization of its properties. CTX-1 was so called because it conferred resistance to cefotaxime. Nucleotide sequence analysis showed that this enzyme had arisen by the accumulation of point mutations in the gene encoding a TEM -lactamase. Consequently, CTX-1 is now named TEM-3. Similarly, SHV-1 has also been called PIT-2: it was first described by Pitton in 1972. 16 Such confusion is typical of studies of -lactamases and can lead to problems when reviewing literature in this area.
Spread of genes conferring resistance to -lactam antibiotics
Throughout the 1960s and 1970s there was a relentless rise in reports of resistance to -lactams as a consequence of the selection of bacteria that produce -lactamases. This increase in the level of resistance was due, at least in part, to the spread of self-transmissible plasmids that encode multiple resistance phenotypes. Furthermore, the first prokaryotic transposon carried a bla TEM gene. 17 Transposons that encode extended-spectrum -lactamases have also been described. 18 The occurrence of bla genes on mobile genetic elements undermines attempts to classify these elements by genetic location: transposons may jump between plasmids and the bacterial chromosome.
The narrow-spectrum -lactamases related to SHV-1 SHV-1 is a narrow-spectrum -lactamase with activity against penicillins. 19 It was first described as a chromosomally encoded -lactamase in members of the genus Klebsiella. Subsequent work demonstrated that SHV-1 is identical to the PIT-2 enzyme, encoded by a transposon and found on plasmids of different incompatibility types. 20 This serves as an illustration of the mobile nature of the genes conferring resistance to -lactam antibiotics. LEN-1 is a chromosomally encoded -lactamase found in many strains of Klebsiella pneumoniae. Nucleotide sequence analysis shows that the gene encoding LEN-1 is very closely related to the nucleotide sequence of the bla SHV-1 gene. Another enzyme with a similar biochemical profile to SHV-1 is OHIO-1. Unlike the gene responsible for the production of LEN-1, the bla OHIO-1 gene is plasmid located. The sequence analysis of OHIO-1 shows that it shares 91.8% amino acid identity with SHV-1. This compares with an identity of 88.9% between the amino acid sequences of SHV-1 and LEN-1 and only a 63.7% identity between the amino acid sequences of SHV-1 and TEM-1.
The enzyme kinetics and biochemical profiles of OHIO-1, LEN-1 and SHV-1 are very similar and resemble those of TEM-1.
1 None of these enzymes is able to hydrolyse extended-spectrum cephalosporins, cephamycins, monobactams or carbapenems. They can, however, inactivate the narrow-spectrum cephalosporins such as cefamandole and cefoperazone and are active against penicillins. Bacteria producing SHV-1 and LEN-1 are distributed globally; OHIO-1 is, at present, restricted to bacteria isolated in the American state of Ohio.
The introduction of extended-spectrum cephalosporins and the emergence of associated extended-spectrum -lactamases
To combat the increasing problem of antibiotic-resistant bacteria, particularly in the hospital setting, extendedspectrum cephalosporins were introduced into clinical practice in the early 1980s. Besides their resistance to hydrolysis by the -lactamases commonly encountered at that time, these antibiotics are also active against Pseudomonas aeruginosa, which is resistant to a diversity of other antibiotics and has traditionally posed considerable therapeutic problems. Cefotaxime was the first of these drugs to be used widely in clinical practice. Ceftazidime and ceftriaxone are other examples of this sub-family. These antibiotics were rapidly adopted and they play an important role in the treatment of potentially life-threatening infections caused by a wide array of bacteria. Because of their broad spectrum of activity, they are of particular value in the initiation of empirical therapy.
By the mid-1980s, resistance to extended-spectrum cephalosporins had appeared in clinically significant Gramnegative bacteria. The basis of this resistance was production of -l a c t a m a s e . 2 1 -2 3 Among the first of the extendedspectrum -lactamases to cause significant clinical problems were mutants derived from the narrow-spectrum SHV-1 or TEM-1 -lactamases. The genes encoding these mutants are present on mobile genetic elements, facilitating their spread in nosocomial pathogens. 1 The first extended-spectrum SHV enzyme was described in 1983 in clinical isolates of K. pneumoniae, Klebsiella ozaenae and Serratia marcescens. 21 Because of its similarity to SHV-1 the new enzyme was named SHV-2. 24 A single amino acid substitution alters the spectrum of activity of the SHV-1 -lactamase to encompass extendedspectrum cephalosporins. Glycine at position 238 in SHV-1 is replaced by serine in SHV-2. 25 In 1988, Jarlier et al. 22 described SHV-3, a -lactamase isolated from K. pneumoniae. This was isolated from a patient in an intensive therapy unit in a French hospital where SHV-2 had also been reported. Both SHV-2 and SHV-3 have a spectrum of activity that includes extendedspectrum cephalosporins and they share a substrate and inhibitor profile. At the nucleotide sequence level, a point mutation causes the substitution of leucine at amino acid position 205 in SHV-3 for the arginine that is found at that position in both SHV-1 and SHV-2. SHV-3 also has a serine residue at amino acid position 238. It is thus probable that it evolved from SHV-2 by a point mutation. This mutation significantly alters the isoelectric point of the enzyme. The isoelectric point of both SHV-1 and SHV-2 is 7.6, whereas that of SHV-3 is 7.0. Soon after the first description of SHV-3, yet another member of this family was described. 26 The SHV-4 -lactamase is another enzyme with extended-spectrum cephalosporinase activity. It was first described from K. pneumoniae and, like SHV-3, it was first seen in a French hospital. Strains of K. pneumoniae that elaborate SHV-4 disseminated rapidly and by 1990 they had been found in 14 hospitals throughout France. 27 The isoelectric point of SHV-4 is 7.8. Analysis of amino acid sequence data shows that SHV-4 evolved by a point mutation in the gene that codes for SHV-3. In the case of SHV-4 the amino acid substitution occurs at position 240, where lysine replaces the glutamic acid found in this position in the other members of the SHV family.
The fifth member of the SHV family was first observed in Chile. 28 This was the first variant not to have been first observed in Europe. SHV-5 was again first described from K. pneumoniae and has an isoelectric point of 8.2. As with SHV-4, the amino acid found at position 240 in SHV-5 is lysine. It is impossible, however, to say from which ancestral gene the SHV-5 determinant evolved: it may have evolved by point mutation from either SHV-4 or SHV-2.
The SHV-6 -lactamase was discovered in 1991. 29 This is an unusual enzyme in that its spectrum of activity is different from other extended-spectrum -lactamases in this family. SHV-6 can hydrolyse ceftazidime but it has no activity against other extended-spectrum cephalosporins such as cefotaxime. It is also inactive against monobactams such as aztreonam, which distinguishes it from other extended-spectrum SHV enzymes. It was first found in France where it was produced by a strain of K. pneumoniae isolated from a patient on a paediatric oncology ward. It is probable that SHV-6 arose by point mutation from SHV-1 since these two enzymes differ only at amino acid position 179 where the aspartic acid found in SHV-1 has been replaced with alanine in SHV-6. 30 The isoelectric point of SHV-6 at 7.6 is indistinguishable from that of SHV-2, illustrating the difficulties of using this as a method of characterizing -lactamases. This also demonstrates the importance of a rapid and reliable method of differentiating members of this family of enzymes.
SHV-type extended-spectrum -lactamases do not only occur in Klebsiella pneumoniae
The first extended-spectrum SHV enzyme to be described in Escherichia coli was in isolates from residents of a nursing home for the elderly in the USA. 31 Its closest evolutionary relative is SHV-5, from which it differs at two positions. The isoleucine found at position 8 in SHV-5 is replaced by phenylalanine in SHV-7 and at position 43 the SHV-5 enzyme has arginine, whereas SHV-7 has serine. The substitution at position 43 alters the isoelectric point of SHV-7 to a value of 7.6. The substitution at position 8 is in the leader sequence and is cleaved from the mature enzyme. Hence, this change will have no effect on the isoelectric point of the mature enzyme. Two mutations are required to derive SHV-7 from SHV-5 and furthermore these are at positions that have not previously been recognized as important in altering the properties of SHV -lactamases. This implies that a currently unidentified member of this family, linking SHV-5 and SHV-7, awaits discovery. E. coli provided the background for the emergence of SHV-8. 32 This was also first observed in the USA. It differs from SHV-1 by the substitution of asparagine in SHV-8 for the aspartic acid seen in SHV-1 at position 179. It is of considerable interest to note that SHV-1 has a relatively narrow spectrum of activity, whereas SHV-8 has significant activity against extended-spectrum cephalosporins and monobactams. SHV-6 also differs from SHV-1 by a single amino acid at this position. In the case of SHV-6, the amino acid is alanine. This substitution has a profound effect upon the activity of this enzyme. It is also of interest that although these mutations affect the spectrum of activity of these three enzymes, they all share the same isoelectric point (7.6).
The SHV-9 -lactamase 33 appears to have evolved from SHV-5 in another two-step process. This enzyme was found to be produced by E. coli, K. pneumoniae and S. marcescens isolated from a Greek Hospital in 1995. It differs from SHV-5 by the substitution of arginine for alanine at position 140. There is also a triplet deletion causing the loss of amino acid 54 from SHV-9. Again, the double change implies that there is another SHV enzyme awaiting discovery. The first inhibitor-resistant SHVlactamase, SHV-10, was first seen produced by E. coli. It is derived from SHV-9 by a single amino acid substitution at position 130. 34 The serine that is typically found in this position has been changed to glycine in SHV-10. Both SHV-9 and SHV-10 have isoelectric points of 8.2.
The latest additions to the SHV family were both first described from Switzerland and are found in a number of species in the Enterobacteriaceae family. 35 SHV-11 is a variant of either SHV-1 or SHV-3 and it does not possess extended-spectrum cephalosporinase activity. It has a glutamine instead of leucine at amino acid 35. SHV-12, an extended-spectrum -lactamase, also has glutamine at position 35 and it probably evolved by a point mutation from SHV-5. To complete the current evolutionary picture (Figures 1 and 2) , either the gene encoding SHV-2 or that encoding SHV-12 has undergone a point mutation to yield SHV-2a. 36 The first report of each of the SHV -lactamases are summarized in Table I .
The structure-function relationship in SHV -lactamases
Study of the amino acid substitutions in the SHV family have led to interesting speculations on the interrelationship between the active sites of these enzymes and their substrates. The availability of nucleotide sequence data and crystal structures for the serine -lactamases has given a greater understanding of the structure-function relationships. 61, 62 In the case of the substitution of serine for glycine at position 238 in SHV-2, the cavity in which the -lactam substrate is accommodated is enlarged. This enables extended-spectrum cephalosporins with their bulky methoxyamino moieties to enter the active site of the enzyme. 62 The consequence of this change is that cefotaxime and ceftazidime are bound with a higher affinity during hydrolysis. There is a disadvantage to this change common to most extended-spectrum -lactamases, in that the -lactam ring is shifted away from the active site serine at position 70. This decreases the efficacy of these enzymes. To compensate for lower enzymic activity, mutations in the promoter sequences may increase the production of extended-spectrum -lactamases. 63 Alternatively, there may be the integration upstream of insertion sequences carrying more potent promoters that thus cause polar mutations. Although the serine for glycine substitution at position 238 is the most frequently encountered change, others also occur. Substitutions of the aspartic acid for asparagine at position 179 in SHV-8 and for alanine in SHV-6 allow the accommodation of the oxyaminocephalosporins in the active site cavity.
Substitutions at other positions increase hydrolytic activity against ceftazidime and aztreonam. The substitution of lysine at position 240 replaces a strongly negatively charged amino acid, glutamic acid, at the bottom of the -pleated sheet. This attracts and binds the terminal carboxyl group on the long oxyamino side chain of these two agents. 64 This substitution is seen in SHV-4, SHV-5 and SHV-7. The first two of these enzymes are now frequently encountered, perhaps reflecting the selective pressure of increased usage of ceftazidime. Substitution of lysine for glutamic acid at position 240 is also seen in SHV-9, SHV-10 and SHV-12, all related to SHV-5. Mutations at position 205 seen in SHV-3 and SHV-4 are located on a helix that lies adjacent to the serine at position 70 in the active site. The precise mechanism by which these alterations contribute to extendedspectrum -lactamase activity is not yet clear. 65 There have been predictions that inhibitor-resistant extended-spectrum -lactamases might arise by selection of SHV -lactamases. It has been proposed that they could acquire a mutation at position 69 where methionine is substituted by isoleucine. Similar alterations have been described in a laboratory mutant of OHIO-1. 66 Mutants of SHV-5 carrying substitutions of isoleucine or valine at position 69 have been constructed. 67 Although resistant to inhibitors such as clavulanate, these mutants display a very marked reduction in resistance to penicillins and cephalosporins with the MICs of cefotaxime, ceftazidime and aztreonam being 2 mg/L, 8-16 mg/L and 8 mg/L, respectively. Alteration at position 69 will affect the positioning of adjacent amino acids and the loss of activity may be due to displacement of the serine at position 70. This is important for binding the -lactam to the active site of the enzyme. Thus, alterations at position 69 may move the adjacent serine away from the substrate. 65 Interestingly, the first inhibitor-resistant SHV -lactamase to arise by natural selection, SHV-10, carries a mutation at position 130 34 rather than at amino acid 69. This illustrates the danger of predicting the course of the natural evolution of genes based upon experiments performed under laboratory conditions. The amino acid substitutions and isoelectric point of each SHV -lactamase are summarized in Table II .
Evolutionary relationships and spread of genes encoding the SHV family of -lactamases
The bla SHV-1 gene, encoding the SHV-1 -lactamase, is commonly encountered in clinical isolates. 1 Its prevalence provides an explanation for the number of variants to which it is directly related. Four enzymes, SHV-2, SHV-6, SHV-8 and SHV-11 all arise from single amino acid substitutions in SHV-1. Indeed, SHV-6 and SHV-8 involve the substitution of different amino acids at the same position. The gene encoding SHV-5 has given rise to five variants, although in this case the existence of two can only be implied by extrapolation of the probable evolutionary path of the secondary derivatives, SHV-7 and SHV-9. It is interesting to speculate on the frequency of mutation focused upon the bla SHV-5 gene. It is unlikely to be due to its numerical prevalence, since it is far less commonly encountered than the bla SHV-1 gene.
It is of interest to note that the early members of the SHV family were all first described in strains of K. pneumoniae. Later, E. coli was also the host for variants in this family. The genes encoding these -lactamases are, however, frequently found on self-transmissible plasmids. They have now been found in other members of the Enterobacteriaceae including important nosocomial pathogens such as Citrobacter diversus, Klebsiella oxytoca and Morganella morganii. They have also been reported to be produced by P. aeruginosa 76 and Burkholderia cepacia. 60 These genes have been mobilized to a wide range of Gramnegative pathogens. There has also been considerable geographical spread of these -lactamases. Although SHV-2 was first described in Germany 21 it, and its variant SHV-2a, has since been seen around the world. Like SHV-2, its variant, SHV-2a, first appeared in Germany. 46 These enzymes have subsequently been found in the USA and are particularly common in countries that border the Mediterranean where they often occur in salmonella isolates. 39 The SHV-5 -lactamase shows a similar widespread geographical distribution. 77 In contrast to SHV-2 and SHV-5, bacteria producing SHV-3 and SHV-4 have been found to be more geographically restricted: they have both only been reported from France. 27, 78 Bacteria producing SHV-4 have, however, been responsible for infections in 14 separate hospitals. This -lactamase has been found in C. diversus as well as K. pneumoniae. 79 It would thus appear to be able to spread with relative ease. Further reports of bacteria that produce this -lactamase are awaited from elsewhere in the world. Other -lactamases of the SHV family tend to occur sporadically. The appearance of variants of the SHV -lactamase in various geographical locations implies co-evolution of these genes, mirroring the convergent evolution described for members of the bla TEM family. 80 The data on geographical distribution of SHV -lactamases are summarized in Table I .
Methods used to characterize members of the SHV family of -lactamase
The methods available for the rapid and reliable identification of -lactamases have been somewhat limited. Many bacteria that produce extended-spectrum -lactamases (ESBLs) appear sensitive to third-generation cephalosporins in disc diffusion sensitivity testing, and may only be apparent because of therapeutic failures or when they are deliberately sought using a double disc diffusion test. 81 Once an ESBL has been identified, the problems of characterization continue.
Biochemical analyses lack discrimination and the determination of isoelectric points is technically demanding and prone to error. Full nucleotide sequence determination provides a definitive identification but this is beyond the scope of a routine diagnostic practice. Consequently, we have developed an identification technique based upon PCR and Single Strand Conformational Polymorphism, (PCR-SSCP). 82 A very short PCR amplimer is generated and the DNA strands are separated and subjected to electrophoretic analysis. Single point mutations alter the conformation of the denatured strands, thus altering the electrophoretic mobility of short products. The precise nature of these changes depends upon the position and nature of the mutation. We have successfully applied PCR-SSCP to the identification of SHV -lactamase genes up to bla and have used it in cases where resistance to -lactam antibiotics is mediated by more than one class oflactamase. 84 The success of this method with the bla SHV-7 gene is significant. The functional mutations that are responsible for the amino acid substitutions in this enzyme fall outside the target for the PCR amplification used in subsequent SSCP analysis. We can successfully apply this technique to the characterization of bla SHV-7 because the gene carries silent mutations that occur within the amplified target DNA. Other bla SHV genes that carry silent mutations within the amplimer target will thus, by extrapolation, be identified using PCR-SSCP. This technique can also be applied to strains that harbour more than one bla SHV gene. 83 In such cases, the two predicted SSCP patterns appear superimposed upon one another. The SSCP technique can be used to provide a rapid and reliable characterization of point mutations in any short DNA sequence. It can thus be applied to the characterization of other resistance determinants where point mutations have a role in the expression of a resistance phenotype. This may include the genes encoding other -lactamases or, indeed, resistance to other antimicrobials.
Conclusions
More than 90% of clinical isolates of K. pneumoniae carry a chromosomal copy of either LEN-1 or SHV-1.
1 Genes encoding SHV-1 are transposable and may be found on plasmids in other bacterial species within the family Enterobacteriaceae. The occurrence of extended-spectrum -lactamases of the SHV family on self-transmissible plasmids illustrates the mobility of this family of enzymes. There have already been reports of bacteria that elaborate both SHV-1 and an extended-spectrum mutant SHV enzyme. 83 We can surely look forward to the first occurrence of a strain that elaborates two extended-spectrum SHV -lactamases. The extended-spectrum -lactamases constitute a serious potential hazard for clinicians attempting to treat patients who are infected with bacteria that express these resistance determinants. The occurrence of two extended-spectrum -lactamases in the same isolate will compound these difficulties. They also provide the opportunity for continuing basic scientific research into the evolution and dissemination of resistance determinants that threaten the continued use of a valuable family of antimicrobial agents.
